School of Medicine
Showing 1-6 of 6 Results
-
Jin Billy Li
Professor of Genetics
Current Research and Scholarly InterestsThe Li Lab is primarily interested in RNA editing mediated by ADAR enzymes. We co-discovered that the major function of RNA editing is to label endogenous dsRNAs as "self" to avoid being recognized as "non-self" by MDA5, a host innate immune dsRNA sensor, leading us to pursue therapeutic applications in cancer, autoimmune diseases, and viral infection. The other major direction of the lab is to develop technologies to harness endogenous ADAR enzymes for site-specific transcriptome engineering.
-
Joseph (Joe) Lipsick
Professor of Pathology and of Genetics
Current Research and Scholarly InterestsFunction and evolution of the Myb oncogene family; function and evolution of E2F transcriptional regulators and RB tumor suppressors; epigenetic regulation of chromatin and chromosomes; cancer genetics.
-
Kyle Loh
Assistant Professor of Developmental Biology (Stem Cell)
BioHow the richly varied cell-types in the human body arise from one embryonic cell is a biological marvel and mystery. We have mapped how human embryonic stem cells develop into over twenty different human cell-types. This roadmap allowed us to generate enriched populations of human liver, bone, heart and blood vessel cells in a Petri dish from embryonic stem cells. Each of these human cells could regenerate their cognate tissue upon injection into respective mouse models, with relevance to regenerative medicine. In addition to developmental and stem cell biology, we have an emerging interest in exploring deadly biosafety level 4 viruses together with our collaborators.
Kyle attended the County College of Morris and Rutgers, and received his Ph.D. from Stanford (working with Irving Weissman), with fellowships from the Hertz Foundation, National Science Foundation and Davidson Institute for Talent Development. He then continued as a Siebel Investigator, and later, as an Assistant Professor and The Anthony DiGenova Endowed Faculty Scholar at Stanford, where he is jointly appointed in the Department of Developmental Biology and Institute for Stem Cell Biology & Regenerative Medicine. Kyle is a Packard Fellow, Pew Scholar, Human Frontier Science Program Young Investigator and Baxter Foundation Faculty Scholar, and his research has been recognized by the NIH Director's Early Independence Award, Forbes 30 Under 30, Harold Weintraub Graduate Award, Hertz Foundation Thesis Prize and A*STAR Investigatorship. -
Sydney X. Lu
Assistant Professor of Medicine (Hematology)
BioSydney Lu is an assistant professor and physician-scientist in the Division of Hematology, Department of Medicine with a broad interest in both normal and abnormal RNA processing in the context of normal physiology and disease states. The laboratory studies translational questions regarding the mechanistic basis of RNA processing abnormalities in malignant blood disorders, their implications for leukemogenesis and cancer biology, as well as resultant therapeutic opportunities.
As a physician, Sydney’s group is particularly focused on dissecting RNA processing abnormalities in primary patient samples and disease-relevant preclinical model systems. Lab members employ a variety of ‘wet-lab’ and computational approaches to study transcriptome abnormalities in (1) states of immune dysfunction, (2) myeloid blood cancers such as myelodysplastic syndromes and acute myeloid leukemia, and (3) lymphoid blood cancers such as chronic lymphocytic leukemia. Additional projects are focused on novel therapeutics, including multiple targeted agents which modulate RNA processing, for the selective treatment of these diseases.
Sydney’s research is/has been supposed by grant funding from the National Cancer Institute, Parker Institute for Cancer Immunotherapy, Leukemia & Lymphoma Society, Aplastic Anemia & Myelodysplastic Syndromes International Foundation, the American Society for Clinical Oncology, the American Society of Hematology, the American Association for Cancer Research, the Paula and Rodger Riney Foundation, the Doris Duke Charitable Foundation, The Gabrielles Angel Foundation for Cancer Research, and the Stanford Cancer Institute.
